Drug Profile
Paclitaxel liposomal - Therapeutics 2000
Latest Information Update: 15 Jan 2022
Price :
$50
*
At a glance
- Originator Therapeutics 2000
- Class Antineoplastics; Diterpenes; Paclitaxels; Skin disorder therapies; Small molecules; Taxanes; Vascular disorder therapies
- Mechanism of Action Tubulin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Lung cancer
Most Recent Events
- 02 Nov 1998 Preclinical development for Lung cancer in USA (Inhalation)